Reduction of oxytocin plasma levels in borderline personality disorder and normalization induced by psychotherapies

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

Borderline personality disorder (BPD) is a severe mental disorder characterized by emotional dysregulation, impulsive behaviors, and difficulties in interpersonal relationships.

Despite the poor understanding of the underlying biological processes, the oxytocin (OXT) system may be involved in and mediate some of BPD's symptomatic and behavioral aspects.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

Fifty BPD patients and 28 healthy controls (HC) participated in the study; patients were randomly assigned to two psychotherapeutic treatments: metacognitive interpersonal therapy and structured clinical management.

Clinical and psychometric measures were assessed, and plasma was collected at baseline (T0) and in patients after 6 (T6) and 12 (T12) months of treatment.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

OXT was quantified by a radioimmunoassay technique.

What Was Measured

To clarify OXT's role in BPD, the researchers assessed its plasma levels and modulations induced by psychotherapies in patients.

PubMed files the paper under topics including Borderline Personality Disorder, Oxytocin and Psychotherapy.

The authors tagged it with the keywords Structured Clinical Management, metacognitive interpersonal therapy, plasma levels and psychotherapies.

What This Means in Plain Language

The paper is a randomized study of Oxytocin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Psychological medicine), a journal based in England.

More context: the Oxytocin compound page, all human trials.